Triiodothyronine (T3), inflammation and mortality risk in patients with acute myocardial infarction. Issue 2 (9th February 2022)

• Record Type: Journal Article
• Authors: Razvi, Salman; Jabbar, Avais; Bano, Arjola; Ingoe, Lorna; Carey, Peter; Junejo, Shahid; Thomas, Honey; Addison, Caroline; Austin, David; Greenwood, John P; Zaman, Azfar G
• Is Part Of: European thyroid journal. Volume 11:Issue 2(2022)
• Publication Date: 2022-02-09
• Subjects: triiodothyronine -- inflammation -- mortality -- acute myocardial infarction; Thyroid gland -- Diseases -- Periodicals; Thyroid Diseases -- Periodicals; 612.44
• DOI: 10.1530/ETJ-21-0085
• Languages: English
• ISSNs: 2235-0640

Abstract

Abstract : Objectives: To study the relationship between serum-free T3 (FT3), C-reactive protein (CRP) and all-cause mortality in patients with acute myocardial infarction (AMI). Design: Prospective multicentre longitudinal cohort study. Methods: Between December 2014 and December 2016, thyroid function and CRP were analysed in AMI (both ST-elevation (STEMI) and non-ST-elevation) patients from the Thyroxine in Acute Myocardial Infarction study. The relationship of FT3 and CRP at baseline with all-cause mortality up to June 2020 was assessed. Mediation analysis was performed to evaluate if CRP mediated the relationship between FT3 and mortality. Results: In 1919 AMI patients (29.2% women, mean (s.d. ) age: 64.2 (12.1) years and 48.7% STEMI) followed over a median (interquartile range) period of 51 (46–58) months, there were 277 (14.4%) deaths. Overall, lower serum FT3 and higher CRP levels were associated with higher risk of mortality. When divided the patients into tertiles based on the levels of FT3 and CRP; the group with the lowest FT3 and highest CRP levels had a 2.5-fold increase in mortality risk (adjusted hazard ratio (95% CI) of 2.48 (1.82–3.16)) compared to the group with the highest FT3 and lowest CRP values. CRP mediated 9.8% (95% CI: 6.1–15.0%) of the relationship between FT3 and mortality. Conclusions: In AMI patients, lower serum FT3 levels on admission are associated with a higher mortality risk, which is partly mediated by inflammation. Adequately designed trials to explore the potential benefits of T3 in AMI patients are required.